BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3458532)

  • 1. Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer.
    Wagener DJ; van Oosterom AT; Mulder JH; Somers R; Mouridsen HT; Cortes Funes H; Thomas D; Sylvester R
    Cancer Treat Rep; 1986 May; 70(5):615-8. PubMed ID: 3458532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Gasparini M; Rouesse J; van Oosterom A; Wagener T; Somers R; Russel JA; Voûte PA; Bramwell V; Thomas D; Sylvester R
    Cancer Treat Rep; 1985 Feb; 69(2):211-3. PubMed ID: 3855699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative administration of high-dose methotrexate for osteosarcoma.
    Chan KW; Knowling MA; Duncan CP; Morton KS
    Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
    Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selected applications of methotrexate alone and in combination in osteosarcoma.
    Pratt CB
    Cancer Treat Rep; 1981; 65 Suppl 1():107-11. PubMed ID: 6976828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
    Wagenaar HC; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave AJ; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla JP; Nooij MA; Poveda A; Scotto di Palumbo V; Vermorken JB
    Gynecol Oncol; 2001 Jun; 81(3):348-54. PubMed ID: 11371121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
    Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate in osteogenic sarcoma.
    Jaffe N; Link MP; Cohen D; Traggis D; Frei E; Watts H; Beardsley GP; Abelson HT
    Natl Cancer Inst Monogr; 1981 Apr; (56):201-6. PubMed ID: 6975438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor).
    Juergens H; Kosloff C; Nirenberg A; Mehta BM; Huvos AG; Rosen G
    Natl Cancer Inst Monogr; 1981 Apr; (56):221-6. PubMed ID: 6975439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7).
    Rosen G; Nirenberg A; Caparros B; Juergens H; Kosloff C; Mehta BM; Marcove RC; Huvos AG
    Natl Cancer Inst Monogr; 1981 Apr; (56):213-20. PubMed ID: 6946291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
    Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.